These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 16224788)
1. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Otey CR; Bandara G; Lalonde J; Takahashi K; Arnold FH Biotechnol Bioeng; 2006 Feb; 93(3):494-9. PubMed ID: 16224788 [TBL] [Abstract][Full Text] [Related]
2. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Yun CH; Kim KH; Kim DH; Jung HC; Pan JG Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492 [TBL] [Abstract][Full Text] [Related]
3. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium. Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913 [TBL] [Abstract][Full Text] [Related]
4. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium. Urlacher VB; Schmid RD Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074 [No Abstract] [Full Text] [Related]
5. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant. Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991 [TBL] [Abstract][Full Text] [Related]
6. Obligatory intermolecular electron-transfer from FAD to FMN in dimeric P450BM-3. Kitazume T; Haines DC; Estabrook RW; Chen B; Peterson JA Biochemistry; 2007 Oct; 46(42):11892-901. PubMed ID: 17902705 [TBL] [Abstract][Full Text] [Related]
10. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation. Oliver CF; Modi S; Sutcliffe MJ; Primrose WU; Lian LY; Roberts GC Biochemistry; 1997 Feb; 36(7):1567-72. PubMed ID: 9048540 [TBL] [Abstract][Full Text] [Related]
11. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858 [TBL] [Abstract][Full Text] [Related]
12. A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3). Dietrich JA; Yoshikuni Y; Fisher KJ; Woolard FX; Ockey D; McPhee DJ; Renninger NS; Chang MC; Baker D; Keasling JD ACS Chem Biol; 2009 Apr; 4(4):261-7. PubMed ID: 19271725 [TBL] [Abstract][Full Text] [Related]
13. Laboratory evolution of cytochrome p450 BM-3 monooxygenase for organic cosolvents. Wong TS; Arnold FH; Schwaneberg U Biotechnol Bioeng; 2004 Feb; 85(3):351-8. PubMed ID: 14748091 [TBL] [Abstract][Full Text] [Related]
14. Altering the regioselectivity of cytochrome P450 CYP102A3 of Bacillus subtilis by using a new versatile assay system. Lentz O; Feenstra A; Habicher T; Hauer B; Schmid RD; Urlacher VB Chembiochem; 2006 Feb; 7(2):345-50. PubMed ID: 16381045 [TBL] [Abstract][Full Text] [Related]
15. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs. Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003 [TBL] [Abstract][Full Text] [Related]
16. Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents. Eiben S; Bartelmäs H; Urlacher VB Appl Microbiol Biotechnol; 2007 Jul; 75(5):1055-61. PubMed ID: 17468867 [TBL] [Abstract][Full Text] [Related]
17. Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs. Kang JY; Ryu SH; Park SH; Cha GS; Kim DH; Kim KH; Hong AW; Ahn T; Pan JG; Joung YH; Kang HS; Yun CH Biotechnol Bioeng; 2014 Jul; 111(7):1313-22. PubMed ID: 24474032 [TBL] [Abstract][Full Text] [Related]
18. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3. Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587 [TBL] [Abstract][Full Text] [Related]
19. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options. Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351 [TBL] [Abstract][Full Text] [Related]
20. High-throughput screens based on NAD(P)H depletion. Glieder A; Meinhold P Methods Mol Biol; 2003; 230():157-70. PubMed ID: 12824579 [No Abstract] [Full Text] [Related] [Next] [New Search]